Pharma & Healthcare
Global Opioid-Induced Constipation Market Research Report 2026
- Mar 14, 26
- ID: 732018
- Pages: 119
- Figures: 124
- Views: 10
This report delivers a comprehensive overview of the global Opioid-Induced Constipation market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Opioid-Induced Constipation. The Opioid-Induced Constipation market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Opioid-Induced Constipation manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Segment by Type
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Opioid-Induced Constipation manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Opioid-Induced Constipation sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Opioid-Induced Constipation manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Segment by Type
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Opioid-Induced Constipation manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Opioid-Induced Constipation sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Opioid-Induced Constipation Market Overview
1.1 Product Definition
1.2 Opioid-Induced Constipation by Type
1.2.1 Global Opioid-Induced Constipation Market Value by Type: 2025 vs 2032
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation by Application
1.3.1 Global Opioid-Induced Constipation Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
1.4.1 Global Opioid-Induced Constipation Revenue 2021–2032
1.4.2 Global Opioid-Induced Constipation Sales 2021–2032
1.4.3 Global Opioid-Induced Constipation Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Opioid-Induced Constipation Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2021–2026)
2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Opioid-Induced Constipation, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Opioid-Induced Constipation, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Opioid-Induced Constipation, Product Types and Applications
2.7 Global Key Manufacturers of Opioid-Induced Constipation, Date of Entry into the Industry
2.8 Global Opioid-Induced Constipation Market Competitive Situation and Trends
2.8.1 Global Opioid-Induced Constipation Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Opioid-Induced Constipation Players Market Share by Revenue
2.8.3 Global Opioid-Induced Constipation Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Opioid-Induced Constipation Market Scenario by Region
3.1 Global Opioid-Induced Constipation Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Opioid-Induced Constipation Sales by Region: 2021–2032
3.2.1 Global Opioid-Induced Constipation Sales by Region: 2021–2026
3.2.2 Global Opioid-Induced Constipation Sales by Region: 2027–2032
3.3 Global Opioid-Induced Constipation Revenue by Region: 2021–2032
3.3.1 Global Opioid-Induced Constipation Revenue by Region: 2021–2026
3.3.2 Global Opioid-Induced Constipation Revenue by Region: 2027–2032
3.4 North America Opioid-Induced Constipation Market Facts & Figures by Country
3.4.1 North America Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Opioid-Induced Constipation Sales by Country (2021–2032)
3.4.3 North America Opioid-Induced Constipation Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Opioid-Induced Constipation Market Facts & Figures by Country
3.5.1 Europe Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Opioid-Induced Constipation Sales by Country (2021–2032)
3.5.3 Europe Opioid-Induced Constipation Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Region
3.6.1 Asia Pacific Opioid-Induced Constipation Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Opioid-Induced Constipation Sales by Region (2021–2032)
3.6.3 Asia Pacific Opioid-Induced Constipation Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
3.7.1 Latin America Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Opioid-Induced Constipation Sales by Country (2021–2032)
3.7.3 Latin America Opioid-Induced Constipation Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
3.8.1 Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2021–2032)
3.8.3 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Opioid-Induced Constipation Sales by Type (2021–2032)
4.1.1 Global Opioid-Induced Constipation Sales by Type (2021–2026)
4.1.2 Global Opioid-Induced Constipation Sales by Type (2027–2032)
4.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2021–2032)
4.2 Global Opioid-Induced Constipation Revenue by Type (2021–2032)
4.2.1 Global Opioid-Induced Constipation Revenue by Type (2021–2026)
4.2.2 Global Opioid-Induced Constipation Revenue by Type (2027–2032)
4.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2021–2032)
4.3 Global Opioid-Induced Constipation Price by Type (2021–2032)
5 Segment by Application
5.1 Global Opioid-Induced Constipation Sales by Application (2021–2032)
5.1.1 Global Opioid-Induced Constipation Sales by Application (2021–2026)
5.1.2 Global Opioid-Induced Constipation Sales by Application (2027–2032)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2021–2032)
5.2 Global Opioid-Induced Constipation Revenue by Application (2021–2032)
5.2.1 Global Opioid-Induced Constipation Revenue by Application (2021–2026)
5.2.2 Global Opioid-Induced Constipation Revenue by Application (2027–2032)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2021–2032)
5.3 Global Opioid-Induced Constipation Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Company Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Opioid-Induced Constipation Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Mallinckrodt
6.4.1 Mallinckrodt Company Information
6.4.2 Mallinckrodt Description and Business Overview
6.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
6.4.5 Mallinckrodt Recent Developments/Updates
6.5 Salix (Bausch Health)
6.5.1 Salix (Bausch Health) Company Information
6.5.2 Salix (Bausch Health) Description and Business Overview
6.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
6.5.5 Salix (Bausch Health) Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Progenics Pharmaceuticals
6.7.1 Progenics Pharmaceuticals Company Information
6.7.2 Progenics Pharmaceuticals Description and Business Overview
6.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.7.5 Progenics Pharmaceuticals Recent Developments/Updates
6.8 Purdue Pharm
6.8.1 Purdue Pharm Company Information
6.8.2 Purdue Pharm Description and Business Overview
6.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
6.8.5 Purdue Pharm Recent Developments/Updates
6.9 Nektar Therapeutics
6.9.1 Nektar Therapeutics Company Information
6.9.2 Nektar Therapeutics Description and Business Overview
6.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
6.9.5 Nektar Therapeutics Recent Developments/Updates
6.10 Daiichi Sankyo
6.10.1 Daiichi Sankyo Company Information
6.10.2 Daiichi Sankyo Description and Business Overview
6.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
6.10.5 Daiichi Sankyo Recent Developments/Updates
6.11 Prestige
6.11.1 Prestige Company Information
6.11.2 Prestige Description and Business Overview
6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
6.11.5 Prestige Recent Developments/Updates
6.12 GSK
6.12.1 GSK Company Information
6.12.2 GSK Description and Business Overview
6.12.3 GSK Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 GSK Opioid-Induced Constipation Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Shionogi
6.13.1 Shionogi Company Information
6.13.2 Shionogi Description and Business Overview
6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
6.13.5 Shionogi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Opioid-Induced Constipation Industry Chain Analysis
7.2 Opioid-Induced Constipation Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Opioid-Induced Constipation Production Mode & Process Analysis
7.4 Opioid-Induced Constipation Sales and Marketing
7.4.1 Opioid-Induced Constipation Sales Channels
7.4.2 Opioid-Induced Constipation Distributors
7.5 Opioid-Induced Constipation Customer Analysis
8 Opioid-Induced Constipation Market Dynamics
8.1 Opioid-Induced Constipation Industry Trends
8.2 Opioid-Induced Constipation Market Drivers
8.3 Opioid-Induced Constipation Market Challenges
8.4 Opioid-Induced Constipation Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Opioid-Induced Constipation by Type
1.2.1 Global Opioid-Induced Constipation Market Value by Type: 2025 vs 2032
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation by Application
1.3.1 Global Opioid-Induced Constipation Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
1.4.1 Global Opioid-Induced Constipation Revenue 2021–2032
1.4.2 Global Opioid-Induced Constipation Sales 2021–2032
1.4.3 Global Opioid-Induced Constipation Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Opioid-Induced Constipation Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2021–2026)
2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Opioid-Induced Constipation, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Opioid-Induced Constipation, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Opioid-Induced Constipation, Product Types and Applications
2.7 Global Key Manufacturers of Opioid-Induced Constipation, Date of Entry into the Industry
2.8 Global Opioid-Induced Constipation Market Competitive Situation and Trends
2.8.1 Global Opioid-Induced Constipation Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Opioid-Induced Constipation Players Market Share by Revenue
2.8.3 Global Opioid-Induced Constipation Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Opioid-Induced Constipation Market Scenario by Region
3.1 Global Opioid-Induced Constipation Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Opioid-Induced Constipation Sales by Region: 2021–2032
3.2.1 Global Opioid-Induced Constipation Sales by Region: 2021–2026
3.2.2 Global Opioid-Induced Constipation Sales by Region: 2027–2032
3.3 Global Opioid-Induced Constipation Revenue by Region: 2021–2032
3.3.1 Global Opioid-Induced Constipation Revenue by Region: 2021–2026
3.3.2 Global Opioid-Induced Constipation Revenue by Region: 2027–2032
3.4 North America Opioid-Induced Constipation Market Facts & Figures by Country
3.4.1 North America Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Opioid-Induced Constipation Sales by Country (2021–2032)
3.4.3 North America Opioid-Induced Constipation Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Opioid-Induced Constipation Market Facts & Figures by Country
3.5.1 Europe Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Opioid-Induced Constipation Sales by Country (2021–2032)
3.5.3 Europe Opioid-Induced Constipation Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Region
3.6.1 Asia Pacific Opioid-Induced Constipation Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Opioid-Induced Constipation Sales by Region (2021–2032)
3.6.3 Asia Pacific Opioid-Induced Constipation Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
3.7.1 Latin America Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Opioid-Induced Constipation Sales by Country (2021–2032)
3.7.3 Latin America Opioid-Induced Constipation Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
3.8.1 Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2021–2032)
3.8.3 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Opioid-Induced Constipation Sales by Type (2021–2032)
4.1.1 Global Opioid-Induced Constipation Sales by Type (2021–2026)
4.1.2 Global Opioid-Induced Constipation Sales by Type (2027–2032)
4.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2021–2032)
4.2 Global Opioid-Induced Constipation Revenue by Type (2021–2032)
4.2.1 Global Opioid-Induced Constipation Revenue by Type (2021–2026)
4.2.2 Global Opioid-Induced Constipation Revenue by Type (2027–2032)
4.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2021–2032)
4.3 Global Opioid-Induced Constipation Price by Type (2021–2032)
5 Segment by Application
5.1 Global Opioid-Induced Constipation Sales by Application (2021–2032)
5.1.1 Global Opioid-Induced Constipation Sales by Application (2021–2026)
5.1.2 Global Opioid-Induced Constipation Sales by Application (2027–2032)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2021–2032)
5.2 Global Opioid-Induced Constipation Revenue by Application (2021–2032)
5.2.1 Global Opioid-Induced Constipation Revenue by Application (2021–2026)
5.2.2 Global Opioid-Induced Constipation Revenue by Application (2027–2032)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2021–2032)
5.3 Global Opioid-Induced Constipation Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Company Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Opioid-Induced Constipation Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Mallinckrodt
6.4.1 Mallinckrodt Company Information
6.4.2 Mallinckrodt Description and Business Overview
6.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
6.4.5 Mallinckrodt Recent Developments/Updates
6.5 Salix (Bausch Health)
6.5.1 Salix (Bausch Health) Company Information
6.5.2 Salix (Bausch Health) Description and Business Overview
6.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
6.5.5 Salix (Bausch Health) Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Progenics Pharmaceuticals
6.7.1 Progenics Pharmaceuticals Company Information
6.7.2 Progenics Pharmaceuticals Description and Business Overview
6.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.7.5 Progenics Pharmaceuticals Recent Developments/Updates
6.8 Purdue Pharm
6.8.1 Purdue Pharm Company Information
6.8.2 Purdue Pharm Description and Business Overview
6.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
6.8.5 Purdue Pharm Recent Developments/Updates
6.9 Nektar Therapeutics
6.9.1 Nektar Therapeutics Company Information
6.9.2 Nektar Therapeutics Description and Business Overview
6.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
6.9.5 Nektar Therapeutics Recent Developments/Updates
6.10 Daiichi Sankyo
6.10.1 Daiichi Sankyo Company Information
6.10.2 Daiichi Sankyo Description and Business Overview
6.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
6.10.5 Daiichi Sankyo Recent Developments/Updates
6.11 Prestige
6.11.1 Prestige Company Information
6.11.2 Prestige Description and Business Overview
6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
6.11.5 Prestige Recent Developments/Updates
6.12 GSK
6.12.1 GSK Company Information
6.12.2 GSK Description and Business Overview
6.12.3 GSK Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 GSK Opioid-Induced Constipation Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Shionogi
6.13.1 Shionogi Company Information
6.13.2 Shionogi Description and Business Overview
6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
6.13.5 Shionogi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Opioid-Induced Constipation Industry Chain Analysis
7.2 Opioid-Induced Constipation Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Opioid-Induced Constipation Production Mode & Process Analysis
7.4 Opioid-Induced Constipation Sales and Marketing
7.4.1 Opioid-Induced Constipation Sales Channels
7.4.2 Opioid-Induced Constipation Distributors
7.5 Opioid-Induced Constipation Customer Analysis
8 Opioid-Induced Constipation Market Dynamics
8.1 Opioid-Induced Constipation Industry Trends
8.2 Opioid-Induced Constipation Market Drivers
8.3 Opioid-Induced Constipation Market Challenges
8.4 Opioid-Induced Constipation Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Opioid-Induced Constipation Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Opioid-Induced Constipation Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Opioid-Induced Constipation Market Competitive Situation by Manufacturers in 2025
Table 4. Global Opioid-Induced Constipation Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Opioid-Induced Constipation Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Opioid-Induced Constipation Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Opioid-Induced Constipation, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Opioid-Induced Constipation, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Opioid-Induced Constipation, Product Types and Applications
Table 12. Global Key Manufacturers of Opioid-Induced Constipation, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Opioid-Induced Constipation Companies by Tier (Tier 1, Tier 2, Tier 3), based on Opioid-Induced Constipation Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Opioid-Induced Constipation Sales by Region (K Units), 2021–2026
Table 18. Global Opioid-Induced Constipation Sales Market Share by Region (2021–2026)
Table 19. Global Opioid-Induced Constipation Sales by Region (K Units), 2027–2032
Table 20. Global Opioid-Induced Constipation Sales Market Share by Region (2027–2032)
Table 21. Global Opioid-Induced Constipation Revenue by Region (US$ Million), 2021–2026
Table 22. Global Opioid-Induced Constipation Revenue Market Share by Region (2021–2026)
Table 23. Global Opioid-Induced Constipation Revenue by Region (US$ Million), 2027–2032
Table 24. Global Opioid-Induced Constipation Revenue Market Share by Region (2027–2032)
Table 25. North America Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 27. North America Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 28. North America Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 29. North America Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 32. Europe Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 33. Europe Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Opioid-Induced Constipation Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Opioid-Induced Constipation Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Opioid-Induced Constipation Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Opioid-Induced Constipation Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Opioid-Induced Constipation Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 42. Latin America Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 43. Latin America Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 50. Global Opioid-Induced Constipation Sales (K Units) by Type (2021–2026)
Table 51. Global Opioid-Induced Constipation Sales (K Units) by Type (2027–2032)
Table 52. Global Opioid-Induced Constipation Sales Market Share by Type (2021–2026)
Table 53. Global Opioid-Induced Constipation Sales Market Share by Type (2027–2032)
Table 54. Global Opioid-Induced Constipation Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Opioid-Induced Constipation Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Opioid-Induced Constipation Revenue Market Share by Type (2021–2026)
Table 57. Global Opioid-Induced Constipation Revenue Market Share by Type (2027–2032)
Table 58. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2021–2026)
Table 59. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2027–2032)
Table 60. Global Opioid-Induced Constipation Sales (K Units) by Application (2021–2026)
Table 61. Global Opioid-Induced Constipation Sales (K Units) by Application (2027–2032)
Table 62. Global Opioid-Induced Constipation Sales Market Share by Application (2021–2026)
Table 63. Global Opioid-Induced Constipation Sales Market Share by Application (2027–2032)
Table 64. Global Opioid-Induced Constipation Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Opioid-Induced Constipation Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Opioid-Induced Constipation Revenue Market Share by Application (2021–2026)
Table 67. Global Opioid-Induced Constipation Revenue Market Share by Application (2027–2032)
Table 68. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2021–2026)
Table 69. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2027–2032)
Table 70. Takeda Pharmaceuticals Company Information
Table 71. Takeda Pharmaceuticals Description and Business Overview
Table 72. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 73. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 74. Takeda Pharmaceuticals Recent Developments/Updates
Table 75. Bayer Company Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 78. Bayer Opioid-Induced Constipation Product
Table 79. Bayer Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 83. Sanofi Opioid-Induced Constipation Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Mallinckrodt Company Information
Table 86. Mallinckrodt Description and Business Overview
Table 87. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 88. Mallinckrodt Opioid-Induced Constipation Product
Table 89. Mallinckrodt Recent Developments/Updates
Table 90. Salix (Bausch Health) Company Information
Table 91. Salix (Bausch Health) Description and Business Overview
Table 92. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 93. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 94. Salix (Bausch Health) Recent Developments/Updates
Table 95. AstraZeneca Company Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 98. AstraZeneca Opioid-Induced Constipation Product
Table 99. AstraZeneca Recent Developments/Updates
Table 100. Progenics Pharmaceuticals Company Information
Table 101. Progenics Pharmaceuticals Description and Business Overview
Table 102. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 103. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 104. Progenics Pharmaceuticals Recent Developments/Updates
Table 105. Purdue Pharm Company Information
Table 106. Purdue Pharm Description and Business Overview
Table 107. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 108. Purdue Pharm Opioid-Induced Constipation Product
Table 109. Purdue Pharm Recent Developments/Updates
Table 110. Nektar Therapeutics Company Information
Table 111. Nektar Therapeutics Description and Business Overview
Table 112. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 113. Nektar Therapeutics Opioid-Induced Constipation Product
Table 114. Nektar Therapeutics Recent Developments/Updates
Table 115. Daiichi Sankyo Company Information
Table 116. Daiichi Sankyo Description and Business Overview
Table 117. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 118. Daiichi Sankyo Opioid-Induced Constipation Product
Table 119. Daiichi Sankyo Recent Developments/Updates
Table 120. Prestige Company Information
Table 121. Prestige Description and Business Overview
Table 122. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 123. Prestige Opioid-Induced Constipation Product
Table 124. Prestige Recent Developments/Updates
Table 125. GSK Company Information
Table 126. GSK Description and Business Overview
Table 127. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 128. GSK Opioid-Induced Constipation Product
Table 129. GSK Recent Developments/Updates
Table 130. Shionogi Company Information
Table 131. Shionogi Description and Business Overview
Table 132. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 133. Shionogi Opioid-Induced Constipation Product
Table 134. Shionogi Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Opioid-Induced Constipation Distributors List
Table 138. Opioid-Induced Constipation Customers List
Table 139. Opioid-Induced Constipation Market Trends
Table 140. Opioid-Induced Constipation Market Drivers
Table 141. Opioid-Induced Constipation Market Challenges
Table 142. Opioid-Induced Constipation Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Opioid-Induced Constipation
Figure 2. Global Opioid-Induced Constipation Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Opioid-Induced Constipation Market Share by Type: 2025 & 2032
Figure 4. Methylnaltrexone Bromide Product Picture
Figure 5. Lubiprostone Product Picture
Figure 6. Naloxegol Product Picture
Figure 7. Others Product Picture
Figure 8. Global Opioid-Induced Constipation Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Opioid-Induced Constipation Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Pharmacy
Figure 12. Other
Figure 13. Global Opioid-Induced Constipation Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Opioid-Induced Constipation Market Size (US$ Million), 2021–2032
Figure 15. Global Opioid-Induced Constipation Sales (K Units), 2021–2032
Figure 16. Global Opioid-Induced Constipation Average Price (USD/Unit), 2021–2032
Figure 17. Opioid-Induced Constipation Report Years Considered
Figure 18. Opioid-Induced Constipation Sales Share by Manufacturers in 2025
Figure 19. Global Opioid-Induced Constipation Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Opioid-Induced Constipation Players: Market Share by Revenue in Opioid-Induced Constipation in 2025
Figure 21. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 24. North America Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 25. U.S. Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 28. Europe Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 29. Germany Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Opioid-Induced Constipation Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Region (2021–2032)
Figure 36. China Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Taiwan Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Indonesia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Thailand Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Malaysia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Philippines Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 47. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 48. Mexico Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. U.A.E Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Opioid-Induced Constipation by Type (2021–2032)
Figure 57. Global Revenue Market Share of Opioid-Induced Constipation by Type (2021–2032)
Figure 58. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Opioid-Induced Constipation by Application (2021–2032)
Figure 60. Global Revenue Market Share of Opioid-Induced Constipation by Application (2021–2032)
Figure 61. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2021–2032)
Figure 62. Opioid-Induced Constipation Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Opioid-Induced Constipation Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Opioid-Induced Constipation Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Opioid-Induced Constipation Market Competitive Situation by Manufacturers in 2025
Table 4. Global Opioid-Induced Constipation Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Opioid-Induced Constipation Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Opioid-Induced Constipation Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Opioid-Induced Constipation, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Opioid-Induced Constipation, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Opioid-Induced Constipation, Product Types and Applications
Table 12. Global Key Manufacturers of Opioid-Induced Constipation, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Opioid-Induced Constipation Companies by Tier (Tier 1, Tier 2, Tier 3), based on Opioid-Induced Constipation Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Opioid-Induced Constipation Sales by Region (K Units), 2021–2026
Table 18. Global Opioid-Induced Constipation Sales Market Share by Region (2021–2026)
Table 19. Global Opioid-Induced Constipation Sales by Region (K Units), 2027–2032
Table 20. Global Opioid-Induced Constipation Sales Market Share by Region (2027–2032)
Table 21. Global Opioid-Induced Constipation Revenue by Region (US$ Million), 2021–2026
Table 22. Global Opioid-Induced Constipation Revenue Market Share by Region (2021–2026)
Table 23. Global Opioid-Induced Constipation Revenue by Region (US$ Million), 2027–2032
Table 24. Global Opioid-Induced Constipation Revenue Market Share by Region (2027–2032)
Table 25. North America Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 27. North America Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 28. North America Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 29. North America Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 32. Europe Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 33. Europe Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Opioid-Induced Constipation Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Opioid-Induced Constipation Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Opioid-Induced Constipation Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Opioid-Induced Constipation Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Opioid-Induced Constipation Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 42. Latin America Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 43. Latin America Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Opioid-Induced Constipation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Opioid-Induced Constipation Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Opioid-Induced Constipation Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Opioid-Induced Constipation Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Opioid-Induced Constipation Revenue by Country (US$ Million), 2027–2032
Table 50. Global Opioid-Induced Constipation Sales (K Units) by Type (2021–2026)
Table 51. Global Opioid-Induced Constipation Sales (K Units) by Type (2027–2032)
Table 52. Global Opioid-Induced Constipation Sales Market Share by Type (2021–2026)
Table 53. Global Opioid-Induced Constipation Sales Market Share by Type (2027–2032)
Table 54. Global Opioid-Induced Constipation Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Opioid-Induced Constipation Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Opioid-Induced Constipation Revenue Market Share by Type (2021–2026)
Table 57. Global Opioid-Induced Constipation Revenue Market Share by Type (2027–2032)
Table 58. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2021–2026)
Table 59. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2027–2032)
Table 60. Global Opioid-Induced Constipation Sales (K Units) by Application (2021–2026)
Table 61. Global Opioid-Induced Constipation Sales (K Units) by Application (2027–2032)
Table 62. Global Opioid-Induced Constipation Sales Market Share by Application (2021–2026)
Table 63. Global Opioid-Induced Constipation Sales Market Share by Application (2027–2032)
Table 64. Global Opioid-Induced Constipation Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Opioid-Induced Constipation Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Opioid-Induced Constipation Revenue Market Share by Application (2021–2026)
Table 67. Global Opioid-Induced Constipation Revenue Market Share by Application (2027–2032)
Table 68. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2021–2026)
Table 69. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2027–2032)
Table 70. Takeda Pharmaceuticals Company Information
Table 71. Takeda Pharmaceuticals Description and Business Overview
Table 72. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 73. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 74. Takeda Pharmaceuticals Recent Developments/Updates
Table 75. Bayer Company Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 78. Bayer Opioid-Induced Constipation Product
Table 79. Bayer Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 83. Sanofi Opioid-Induced Constipation Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Mallinckrodt Company Information
Table 86. Mallinckrodt Description and Business Overview
Table 87. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 88. Mallinckrodt Opioid-Induced Constipation Product
Table 89. Mallinckrodt Recent Developments/Updates
Table 90. Salix (Bausch Health) Company Information
Table 91. Salix (Bausch Health) Description and Business Overview
Table 92. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 93. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 94. Salix (Bausch Health) Recent Developments/Updates
Table 95. AstraZeneca Company Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 98. AstraZeneca Opioid-Induced Constipation Product
Table 99. AstraZeneca Recent Developments/Updates
Table 100. Progenics Pharmaceuticals Company Information
Table 101. Progenics Pharmaceuticals Description and Business Overview
Table 102. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 103. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 104. Progenics Pharmaceuticals Recent Developments/Updates
Table 105. Purdue Pharm Company Information
Table 106. Purdue Pharm Description and Business Overview
Table 107. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 108. Purdue Pharm Opioid-Induced Constipation Product
Table 109. Purdue Pharm Recent Developments/Updates
Table 110. Nektar Therapeutics Company Information
Table 111. Nektar Therapeutics Description and Business Overview
Table 112. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 113. Nektar Therapeutics Opioid-Induced Constipation Product
Table 114. Nektar Therapeutics Recent Developments/Updates
Table 115. Daiichi Sankyo Company Information
Table 116. Daiichi Sankyo Description and Business Overview
Table 117. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 118. Daiichi Sankyo Opioid-Induced Constipation Product
Table 119. Daiichi Sankyo Recent Developments/Updates
Table 120. Prestige Company Information
Table 121. Prestige Description and Business Overview
Table 122. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 123. Prestige Opioid-Induced Constipation Product
Table 124. Prestige Recent Developments/Updates
Table 125. GSK Company Information
Table 126. GSK Description and Business Overview
Table 127. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 128. GSK Opioid-Induced Constipation Product
Table 129. GSK Recent Developments/Updates
Table 130. Shionogi Company Information
Table 131. Shionogi Description and Business Overview
Table 132. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 133. Shionogi Opioid-Induced Constipation Product
Table 134. Shionogi Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Opioid-Induced Constipation Distributors List
Table 138. Opioid-Induced Constipation Customers List
Table 139. Opioid-Induced Constipation Market Trends
Table 140. Opioid-Induced Constipation Market Drivers
Table 141. Opioid-Induced Constipation Market Challenges
Table 142. Opioid-Induced Constipation Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Opioid-Induced Constipation
Figure 2. Global Opioid-Induced Constipation Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Opioid-Induced Constipation Market Share by Type: 2025 & 2032
Figure 4. Methylnaltrexone Bromide Product Picture
Figure 5. Lubiprostone Product Picture
Figure 6. Naloxegol Product Picture
Figure 7. Others Product Picture
Figure 8. Global Opioid-Induced Constipation Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Opioid-Induced Constipation Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Pharmacy
Figure 12. Other
Figure 13. Global Opioid-Induced Constipation Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Opioid-Induced Constipation Market Size (US$ Million), 2021–2032
Figure 15. Global Opioid-Induced Constipation Sales (K Units), 2021–2032
Figure 16. Global Opioid-Induced Constipation Average Price (USD/Unit), 2021–2032
Figure 17. Opioid-Induced Constipation Report Years Considered
Figure 18. Opioid-Induced Constipation Sales Share by Manufacturers in 2025
Figure 19. Global Opioid-Induced Constipation Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Opioid-Induced Constipation Players: Market Share by Revenue in Opioid-Induced Constipation in 2025
Figure 21. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 24. North America Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 25. U.S. Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 28. Europe Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 29. Germany Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Opioid-Induced Constipation Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Region (2021–2032)
Figure 36. China Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Taiwan Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Indonesia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Thailand Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Malaysia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Philippines Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 47. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 48. Mexico Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. U.A.E Opioid-Induced Constipation Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Opioid-Induced Constipation by Type (2021–2032)
Figure 57. Global Revenue Market Share of Opioid-Induced Constipation by Type (2021–2032)
Figure 58. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Opioid-Induced Constipation by Application (2021–2032)
Figure 60. Global Revenue Market Share of Opioid-Induced Constipation by Application (2021–2032)
Figure 61. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2021–2032)
Figure 62. Opioid-Induced Constipation Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232